Physician

Aleksandra Granath, M.D. ,PH.D.

According to 2025 Medicare claims, Aleksandra Granath, M.D. , PH.D. (NPI: 1366531535) practices rheumatology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is NAPLES RHEUMATOLOGY PLLC (NPI: 1679992028; TIN: 465146856) and primary practice location at 34109-0920. Granath is affiliated with the Honest MSSP of Michigan LLC (ACO ID: A5616), participating under the MSSP model.

Granath's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 249 traditional Medicare patients, billed 241,559 HCPCS/CPT codes, and received $1,278,327 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,462 prescription claims across 218 beneficiaries totaling $1,200,119 in drug costs, led by Cimzia (2 Pack) (Certolizumab Pegol). 2018 DME data shows 13 claims. Open Payments data shows 7 records totaling $361. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $209,012 to $1,278,327. Concurrently, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	497	4,764	$209,012
2016	450	2,529	$165,690
2017	400	80,884	$629,983
2018	355	213,394	$1,521,232
2019	306	205,860	$1,559,263
2020	275	234,652	$1,886,772
2021	252	237,808	$1,797,955
2022	243	233,797	$1,448,099
2023	244	230,884	$1,322,857
2024	249	241,559	$1,278,327

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	380	2,747	$730,554
2016	399	3,400	$1,125,587
2017	375	3,057	$1,309,288
2018	321	2,792	$1,312,471
2019	271	2,115	$1,245,798
2020	257	2,049	$1,266,375
2021	247	1,811	$1,186,166
2022	240	1,622	$1,091,934
2023	227	1,594	$1,246,254
2024	218	1,462	$1,200,119

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	13	14	$506
2018	13	13	$578
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	195	449	$138
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	122	210	$101
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	54	1,119	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	218	525	$13
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	54	223,600	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cimzia (2 Pack)	Certolizumab Pegol	63	2,044	$419,040
Humira(Cf) Pen	Adalimumab	27	896	$225,905
Enbrel Sureclick	Etanercept	26	728	$210,207
Orencia Clickject	Abatacept	23	868	$168,528
Actemra	Tocilizumab	18	504	$83,981

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$361	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aleksandra Granath, M.D. , PH.D.?

Tedicare shows public-source Medicare data for Aleksandra Granath, M.D. , PH.D. (NPI 1366531535), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aleksandra Granath, M.D. , PH.D. have ACO affiliation data?

Aleksandra Granath, M.D. , PH.D. is shown with ACO affiliation data for Honest MSSP of Michigan LLC (MSSP, ACO ID A5616).

What billing organization is linked to Aleksandra Granath, M.D. , PH.D.?

Aleksandra Granath, M.D. , PH.D. is linked to NAPLES RHEUMATOLOGY PLLC (billing NPI 1679992028) in the available physician profile data.

Does Aleksandra Granath, M.D. , PH.D. have Open Payments data?

Aleksandra Granath, M.D. , PH.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.